Publicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (146)

2024

  1. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  2. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 4, pp. 224-231.e2

  3. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 24, pp. 2873-2886

  4. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  5. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

  6. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  7. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

    Cytotherapy, Vol. 26, Núm. 7, pp. 681-685

  8. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

  9. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

  10. Genome-Wide Gene-Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 33, Núm. 3, pp. 400-410

  11. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

    npj Genomic Medicine, Vol. 9, Núm. 1

  12. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12

  13. Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study

    Bone Marrow Transplantation, Vol. 59, Núm. 5, pp. 604-614

  14. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 38, Núm. 9, pp. 1985-1991

  15. International Delphi Consensus Study on disposable single-use endoscopy: A path to clinical adoption

    Digestive and Liver Disease, Vol. 56, Núm. 2, pp. 322-329

  16. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  17. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

    Leukemia

  18. Multiple Myeloma

    The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies (Springer International Publishing), pp. 741-749

  19. Penumbral Rescue by normobaric O = O administration in patients with ischemic stroke and target mismatch proFile (PROOF): Study protocol of a phase IIb trial

    International Journal of Stroke, Vol. 19, Núm. 1, pp. 120-126

  20. Predictors of anastomotic leak and conduit necrosis after oesophagectomy: Results from the oesophago-gastric anastomosis audit (OGAA)

    European Journal of Surgical Oncology, Vol. 50, Núm. 6